MIYUN, China - iSportsWire -- Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regulations of the European Medicines Agency.

Certificate information:

• Company name: Beijing Beilu pharmaceutical Co., Ltd.
• Manufacturing address: No.3 Shuiyuan West Road, Miyun District, Beijing, China
• Registration number: RVG 132878
• Drug name: Iohexol injection 350mg(I)/ml
• Issuing authority: Netherlands Medicines Evaluation Board (MEB)

The successful registration of Iohexol Injection in Netherland indicates that the product has undergone rigorous scientific evaluation by EMA, confirming its compliance with EU Good Manufacturing Practice (GMP), quality, safety and efficacy standards. This authorization enables commercial distribution in EU-approved countries. It creates conditions for speeding up the Mutual recognition procedures(MRP) among EU countries such as Germany, France, Italy and others as well. This will help Beilu Pharmaceutical further promote the expansion of its overseas market and enhance the international market competitiveness of its contrast agent products, which is expected to have a positive impact on the company's operations in the future.

More on iSports Wire

• Live Good Relaunches "Be The Generation" Initiative to Empower Student Leadership Amid Cuts to Public Health and Education
• Host Your Next Retreat in Costa Rica: Tamarindo Bay Boutique Hotel & Studios Offers the Ideal Setting in Playa Tamarindo, Costa Rica
• Koplon Implant & Family Dentistry Receives National Recognition as One of the Best Dental Implant Practices in the U.S
• San Antonio Buyer Secures 2.375% Mortgage in 2025-Broker Reveals the Mistake Costing Buyers Thousands
• Heritage at South Brunswick Grand Opening Success!

Contact Information:
Beijing Beilu Pharmaceutical Co., Ltd.
https://www.beilupharma.com/
yanglm@beilupharma.com